Shield Therapeutics PLC's (LON:STX) Tim Watts talks to Proactive London's Andrew Scott about the reanalysis of the AEGIS-H2H study for its lead product Feraccru. He says the study was intended to provide data comparing oral Feraccru /Accrufer against intravenous iron therapy, to allow economic data capture and analysis.
10 Aug 20